ON-DEMAND WEBINARS

Our latest insights on-demand

Unique Advantages of Incorporating Untargeted and Targeted Metabolomics in Drug Development and Clinical Trials

How United Therapeutics leverages metabolomics to get closer to the phenotype increasing confidence in clinical trial decisions

Deeper Understanding of COVID-19 Phenotypes Through Metabolomics: A Panel Discussion

How are researchers studying COVID-19 using metabolomics to get closer to the phenotype?

Untargeted Metabolomics in Feces a Functional Readout of Gut Microbial Activity

Featuring Annie Evans, Ph.D

Secret Weapon – Interrogating Host Pathogen Interactions with Precision Metabolomics

Featuring Geoffrey Feld, Ph.D

Quality Control and Assurance in Untargeted Metabolomics

Featuring Annie Evans, Ph.D

Precision Metabolomics: Current State and Future Plans

Featuring Luke Miller, Ph.D

Overcoming Challenges in Microbiome Research: A Panel Discussion

Featuring Nikole E. Kimes, PhD, President, CEO & Co-founder at Siolta Therapeutics, Eran Segal, Ph.D., Professor at Weizmann Institute of Science, and Greg Michelotti, Ph.D, Scientific Director of Biology at Metabolon, Inc.

Metabolomics as a Leading Technology in Biomarker Discovery

Featuring Dr. Brian Keppler, Ph.D

Metabolomic Approaches in NASH and NAFLD R&D

Featuring Dr. Jamie Bates of Gilead Sciences and Dr. Kari Wong of Metabolon

How Metabolomic Profiling Can Unlock Gene Function & Provide Biological Insight

Featuring Gregory Michelotti, Ph.D

Harnessing the True Power of Metabolomics with the 4Cs

Featuring Greg Michelotti, Ph.D, Annie Evans, Ph.D, and Kirk Beebe Ph.D

Global Metabolomics & Diabetes: Stories from the Bench to the Clinic

Featuring Kirk Pappan, Ph.D

Mechanisms of Immune Control and Metabolomics

Featuring Vinay Pawar, Ph.D and Ujjwal Neogi, Ph.D., Associate Professor of Virology, Karolinska Institutet and Adjunct Associate Professor, School of Medicine, University of Missouri

Power Your Study For Success

Our experts talk about our well-established best practices and client support solutions that ensure you research the guidance and insights you require to advance your research objectives.

Reflections of the Human Gut Microbiome in the Blood Metabolome

Featuring Sean Gibbons, Ph.D, Assistant Professor at ISB, and Greg Michelotti, Ph.D, Scientific Director of Biology at Metabolon

Understanding Viral Infection & Optimizing Vaccine Development with Metabolomics

Featuring Brian Keppler, Ph.D

Metabolomics and the Microbiome Revolution: Critical Innovations to Unlock Gut Microbial Function in Human Health

Explore how metabolomics enables a unique and critical understanding of gut microbiome function in vivo as well as how recent technical innovations help overcome cold-chain requirements and other challenges related to the collection, storage, and shipping of human fecal metabolomic samples.

Driving COVID-19 Research Forward

Featuring Patricia Sheridan, Ph.D and Dr. James R. Heath, President and Professor at Institute for Systems Biology in Seattle (ISB)

Answering Common Questions About Metabolomics

Featuring Kari Wong, Ph.D, Michael Fanelli, and Vinay Pawar, Ph.D

Metabolomics in Bioprocessing: Enabling Understanding & Control of Active Biology

How metabolomics can be applied across the bioprocess lifecycle from process development to monitoring to gain biological insight and facilitate the development, implementation, and execution of robust and reproducible bioprocesses.

See how Metabolon can advance your path to preclinical and clinical insights

Get A Project Quote

References

1. Zgoda-Pols, J.R., et al., Metabolomics analysis reveals elevation of 3-indoxyl sulfate in plasma and brain during chemically-induced acute kidney injury in mice: investigation of nicotinic acid receptor agonists. Toxicol Appl Pharmacol, 2011. 255(1): p. 48-56.

2. Bryant, J.A., et al., The impact of an oral purified microbiome therapeutic on the gastrointestinal microbiome. Nat Med, 2026. 32(1): p. 186-196

3. McGovern, B .H., et al., SER-109, an Investigational Microbiome Drugto Reduce Recurrence After Clostridioides difficile Infection: Lessons Learned From a Phase 2 Trial. Clin Infect Dis, 2021. 72(12): p. 2132-2140.

4. Feuerstadt, P., et al., SER-109, an Oral Microbiome Therapy for Recurrent Clostridioides difficile Infection. N Engl J Med, 2022. 386(3): p. 220-229.

5. Hu, Z., et al., Targeted metabolomics reveals novel diagnostic biomarkers for colorectal cancer. Mol Oncol, 2025. 19(6): p. 1737-1750.

6. Butler, F.M., et al., Vegetarian Dietary Patterns and Diet-Related Metabolites Are Associated With Kidney Function in the Adventist Health Study-2 Cohort. J Ren Nutr, 2025.

7. Stanford, J., et al., Metabolomic Profiling and Diet Quality Scoring in a Randomized Crossover Trial of Healthy and Typical Dietary Patterns. Mol Nutr Food Res, 2025 . 69(23): p. e70271.

8. O’Connor, L.E., et al., Metabolomic Profiling of an Ultraprocessed Dietary Pattern in a Domiciled Randomized Controlled Crossover Feeding Trial. J Nutr, 2023. 153(8): p. 2181-2192.

9. Fritsch, D.A., et al., Microbiome function underpins the efficacy of a fiber-supplemented dietary intervention in dogs with chronic large bowel diarrhea. BMC Vet Res, 2022. 18(1): p. 245.

10. Leal, L.N., et al., Preweaning nutrient supply improves lactation productivity and reduces the risk of culling in Holstein cows. J Dairy Sci, 2025. 108(6): p. 5875-5888.

11. Ahsin, M., et al., Soil and pasture health underlie improved beef nutrient density determined by untargeted metabolomics in Southern US grass finished beef systems. NPJ Sci Food, 2025. 9(1): p. 151.

12. Yin, W., et al., Plasma lipid profiling across species for the identification of optimal animal models of human dyslipidemia. J Lipid Res, 2012. 53(1): p. 51-65.

13. Porter, F .D., et al., Cholesterol oxidation products are sensitive and specific blood-based biomarkers for Niemann-Pick C1 disease. Sci Transl Med, 2010. 2(56): p. 56ra81.

14. Needham, B .D., et al., Plasma and Fecal Metabolite Profiles in Autism Spectrum Disorder. Biol Psychiatry, 2021. 89(5): p. 451-462

15. Li, C., et al., Estradiol and mTORC2 cooperate to enhance prostaglandin biosynthesis and tumorigenesis in TSC2-deficient LAM cells. J Exp Med, 2014. 211(1): p. 15-28.

16. Green, P.G., et al., Metabolic flexibility and reverse remodelling of the failing human heart. Eur Heart J, 2025. 46(25): p. 2422-2433.

17. Maekawa, H., et al., SGLT2 inhibition protects kidney function by SAM-dependent epigenetic repression of inflammatory genes under metabolic stress. J Clin Invest, 2025. 135(19).

18. Wu, D., et al., Integrated screens reveal that guanine nucleotide depletion, which is irreversible via targeting IMPDH2, inhibits pancreatic cancer and potentiates KRAS inhibition. Gut, 2026.

19. Schwerdtfeger, L.A., et al., Gut microbiota and metabolites are linked to disease progression in multiple sclerosis. Cell Rep Med, 2025. 6(4): p. 102055.

20. Wu, H., et al., Microbiome-metabolome dynamics associated with impaired glucose control and responses to lifestyle changes. Nat Med, 2025. 31(7): p. 2222-2231.

21. Jacobs, J.P., et al., Cognitive behavioral therapy for irritable bowel syndrome induces bidirectional alterations in the brain-gut-microbiome axis associated with gastrointestinal symptom improvement. Microbiome, 2021. 9(1): p. 236.

22. Pietzner, M., et al., Plasma metabolites to profile pathways in noncommunicable disease multimorbidity. Nat Med, 2021. 27(3): p. 471-479.

23. Faquih, T.O., et al., Robust Metabolomic Age Prediction Based on a Wide Selection of Metabolites. J Gerontol A Biol Sci Med Sci, 2025. 80(3).

24. Scherer, N., et al., Coupling metabolomics and exome sequencing reveals graded effects of rare damaging heterozygous variants on gene function and human traits. Nat Genet, 2025. 57(1): p. 193-205.

25. Holmes, Z.C., et al., Untargeted metabolomic analysis of human milk from healthy mothers reveals drivers of metabolite variability. Sci Rep, 2024. 14(1): p. 20827.

26. Titz, B., et al., Implications of Ocular Confounding Factors for Aqueous Humor Proteomic and Metabolomic Analyses in Retinal Diseases. Transl Vis Sci Technol, 2024. 13(6): p. 17.

27. Bloom, S.M., et al., Cysteine dependence of Lactobacillus iners is a potential therapeutic target for vaginal microbiota modulation. Nat Microbiol, 2022. 7(3): p. 434-450.

28. Leimer, E.M., et al., Lipid profile of human synovial fluid following intra-articular ankle fracture. J Orthop Res, 2017. 35(3): p. 657-666.